Background
==========

Stroke is a leading cause of death and disability globally, with 69% of all strokes experienced among people in low- and middle-income countries (LMIC). China is the most populous LMIC and acute stroke the leading cerebrovascular disease. Among stroke survivors, 70--80% are living with varying degrees of neurological impairment, and stroke is associated with high mortality and disability \[[@b1-medscimonit-25-2186]\]. The incidence of acute stroke is increasing year by year, which brings a heavy burden to families and society. The occurrence of acute stroke has a close relationship with atherosclerosis, hemorheological changes, inflammatory state, oxidative stress, and many other factors. Neuronal cell death is the main injury caused by stroke, and its mechanism is by oxidative stress, inflammation, ischemia, hypoxia, calcium ion dysregulation, and apoptosis \[[@b2-medscimonit-25-2186],[@b3-medscimonit-25-2186]\].

Metformin is a clinically common first-line agent for the treatment of type 2 diabetes. Researchers have shown that long-term metformin treatment can reduce the risk of dementia and stroke, and improve the mild cognitive impairment in type 2 diabetes, and metformin may be a potential therapeutic drug for stroke \[[@b4-medscimonit-25-2186]--[@b7-medscimonit-25-2186]\]. AMPK (adenosine monophosphate-activated protein kinase) is an important serine/threonine protein kinase, and is an upstream regulator of key enzymes in oxide synthesis and fat metabolism. Cell energy loss induces an increase in AMP/ATP ratio, which can directly activate AMPK. This process can transform cells from anabolic to catabolic mode, regulate energy metabolism by promoting glycolysis and fatty acid oxidation, and prevent gluconeogenesis \[[@b8-medscimonit-25-2186],[@b9-medscimonit-25-2186]\]. The AMPK/mTOR (mammalian target of rapamycin) signaling pathway plays an important role in cell proliferation, survival, apoptosis, glucose metabolism, gene transcription, and cell migration \[[@b10-medscimonit-25-2186],[@b11-medscimonit-25-2186]\]. Animal experiments have confirmed that metformin influences the formation of beta amyloid protein in dementia model rat neural cells, reduces apoptosis of neurons in rats, and improve memory function of dementia rats through the AMPK/mTOR signaling pathway. Metformin can reduce the area of cerebral infarction and reduce neuronal apoptosis in rats with cerebral ischemia, which is related to the AMPK signaling pathway and the decreased level of oxidative stress \[[@b12-medscimonit-25-2186],[@b13-medscimonit-25-2186]\].

The aim of this study was to investigate the potential neuroprotective effects of metformin and explore the possible mechanisms involved in the primary fetal rat hippocampal neurons deprived of oxygen and glucose (*in vitro* model of stroke). We also investigated the effect of metformin on the functional level of patients following acute stroke combined with type 2 diabetes.

Clinical Data
=============

Research objects
----------------

From January 2014 to December 2016, 80 cases of newly diagnosed acute stroke combined with type 2 diabetes mellitus in our hospital were enrolled in the study, including 46 males and 34 females, with an average age of 58.2±14.6 years. They were randomly divided into 2 groups -- a metformin combined with insulin treatment group and an insulin treatment group -- with 40 cases in each group. There was no significant difference in gender, age, time from onset to visiting, or number of coronary heart disease cases in the 2 groups before treatment (P\>0.05).

Criteria for the admission of cases: (1) all patients were diagnosed with acute ischemic cerebral stroke according to the "China Guidelines for Cerebral Vascular Disease"; (2) patients with first acute stroke were diagnosed by head CT or MRI; (3) patients were diagnosed with type 2 diabetes, with fasting blood glucose ≥7 mmol/L or random blood glucose ≥11.1mmol/L; (4) patients were in stable condition, without serious complications such as liver or kidney dysfunction, myocardial infarction, heart failure, respiratory failure, or pulmonary infection; (5) no cerebral hemorrhage; and (6) the patient and family members volunteered to participate in this study, and the compliance was good. This study was approved by the Ethics Committee of our institute, and all patients signed informed consent before treatment.

Other exclusion factors included presence of: (1) severe liver, cardiovascular, hematopoietic system, urinary system diseases, or tumors; (2) acute or chronic infections; and (3) mental disorders and other incompatible patients.

Other exclusion factors included presence of acute or chronic infection, severe cardiovascular and cerebrovascular events, and other serious complications or adverse reactions during the study period. Subjects were free to withdraw from this study at any time.

Material and methods
--------------------

All patients with acute stroke were immediately treatment with standard treatment after hospitalization, including antiplatelet, anticoagulation, thrombolysis, control of blood pressure, lipid, dehydration reducing intracranial pressure, protection of brain cells, and nerve nutrition, and dietary therapy was carried out according to the diabetes diet. The insulin group was treatment with insulin aspart (NovoRapid R, Novo Nordisk Pharmaceutical, China) subcutaneous injection before the meal, combined with Isophane Protamine Biosynthetic Human Insulin Injection before bedtime (Novolin N, Novo Nordisk Pharmaceutical, China). In the metformin combination treatment group, we added metformin on the basis of the treatment plan of the control group, at 500 mg 3 times a day (Gehua Zhi, Sino-US Shanghai Squibb Pharmaceutical Co.). The dosage of insulin and metformin was adjusted according to the levels of blood glucose. The duration of treatment was 2 weeks.

Assessments
-----------

The following indexes were measured at the end of the 2 weeks before and after the treatment: (1) the nerve function index: Comprehensive assessment was based on the Mini-Mental State Examination (MMSE), National Institutes of Health Stroke Scale (NIHSS), and daily life ability scale (Activities of Daily Living, ADL). (2) Oxidative stress related indicators: Microplate method for the detection of malondialdehyde (MDA), colorimetric method for measuring glutathione peroxidase (GSH-PX) and superoxide dismutase (SOD), the malondialdehyde test kit (A003), the glutathione peroxidase test kit (A005), and the superoxide dismutase kit (A001) were purchased from Nanjing Jiancheng Biotechnology Co. and used strictly in accordance with the instructions.

Basic Research
==============

Materials and methods
---------------------

In the animal experiment, SD rats pregnant for 17 days were purchased from Beijing Weitong Lihua Co.

Main reagents were: DMEM medium, Neurobasal medium, fetal bovine serum (FBS), horse serum, B27 medium additive, pancreatin, penicillin, and streptomycin were purchased from Gibco USA. 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT), poly-L-lysine, DMSO, bovine serum albumin, metformin and TUNEL kit were purchased from Sigma USA. B cell lymphoma/leukemia protein -2 gene (Bcl-2), Bcl-2-associated X protein gene protein (Bcl-2 X), AMPK, phosphorylation pAMPK, rapamycin (mammalian target of rapamycin, mTOR) and rabbit polyclonal antibody were purchased from the Abcam USA. Rat polyclonal antibody of β-actin, second antibody of goat anti-rabbit and goat anti-mouse were bought from Zhonghua Jinqiao Co., China. Caspase-3 activity assay kits and protein assay kits were purchased from Beijing Pulilai Company, China. ECL chemiluminescence kits were purchased from Millipore USA. The MDA and SOD kits were purchased from the Nanjing Jiancheng Bioengineering Institute in China.

Primary neuronal cell culture
-----------------------------

Animal experiments were approved by the local animal ethics committee. The primary fetal rat hippocampal neurons were derived from the embryos of 17-days pregnant SD rats. An anatomic microscope was used to dissect the hippocampus of rats and put it into the Hank 's balanced salt solution. The primary fetal rat hippocampal tissue was digested with 0.25% trypsin at 37°C for 18 min, then oscillated 2\~3 times. The digestion phase was stopped by DMEM culture solution containing 10% FBS. The cell suspension was then obtained by repeating aspirations through a Pasteur pipette following centrifugation at 1500×g for 5 min. The cells were cultured in plates coated with poly-L-lysine (0.1 g/L) with a density of 1×10^5^/mL. The cultures were maintained in a humidified incubator with 5% CO~2~ at 37°C. Penicillin 100U/mL, streptomycin 100U/mL, 10% FBS, and 10% horse serum were added into the culture solution. After 24 h, the total amount of liquid was changed into Neurobasal+B27 serum-free culture system (sugar concentration 25 mmol/L), and this medium was subsequently half-changed every 3 days. The neuronal cells were used for experiment at 7 days.

The primary fetal rat hippocampal neurons, gradually matured after 7 days of culture, were used for cell experiments. The experimental group was divided into the control group (Con), the oxygen-glucose deprivation model group (Mod), and the metformin group (Met). On the seventh day of cell culture, metformin was diluted with culture medium, and for the metformin group we added metformin with the final concentration of 10 mmol/L, while in the control group and model group we added equal volumes of culture medium. The model group and the metformin group were then subjected to oxygen-glucose deprivation for 1 h, but the control group was not.

Oxygen-glucose deprivation treatment of primary fetal rat hippocampal neuron cells
----------------------------------------------------------------------------------

The media in both model and metformin groups were carefully removed, washed with PBS 3 times, and transferred into glucose-free DMEM medium, then the cultured cells were transferred to a hypoxic incubator chamber containing 5% CO~2~ and 95% N~2~ at 37°C for 1 h. After the medium was removed, neurons were exposed to normal growth conditions at 37°C in a humidified incubator with 5% CO~2~ and 95% air for an additional 24 h.

Morphological study of hippocampal neurons
------------------------------------------

The cell growth was observed under a microscope (Leica, Germany).

MTT detection of survival rate
------------------------------

Neuronal cells activity was measured using the MTT method. We added 0.5 mg/mL MTT to each well and incubated for 4 h, then the liquid was discarded. 150μL DMSO was added to each well, and was shocked for 10 min. The enzyme absorbance (OD) was measured at 570 nm. The cell survival rate=(the average value of OD in the experimental group/the mean value of the OD in the control group)×100%.

TUNEL detection of apoptosis rate
---------------------------------

The primary fetal rat hippocampal neuronal cells were placed 24-well clusters with a density of 5×10^4^ cells/well, with coverslip coated by poly-L-lysine in the bottom for drug treatment and the treatment of oxygen-glucose deprivation. TUNEL and PI staining were carried out according to the TUNEL kit instructions. After PBS scrubbing, the morphology of the cells was observed by fluorescence microscope. Cells were counted in 20 fields of vision, selected randomly. We estimated the percentage of apoptotic cells using the following ratio: number of apoptotic cells/total cell number×100%.

Western blot assay of proteins related to apoptotic pathway (AMPK/pAMPK/mTOR/BAX/Bcl-2)
---------------------------------------------------------------------------------------

The primary fetal rat hippocampal neurons cells were placed a culture flask, and after the treatment with drugs and oxygen-glucose deprivation, cells were collected and trypsinized. The protein quantitative kit was used for protein quantification, and equivalent amounts of protein were separated on 12% SDS-polyacrylamide gels and transferred to PVDF membranes. Membranes were incubated with TBS containing 5% nonfat dry milk to block nonspecific binding overnight at 4°C, and were incubated with antibodies against BAX, BCL-2, AMPK, pAMPK, and mTOR at room temperature for 2 h. After being washed with TBST 3 times for 10 min each time, membranes were incubated with secondary antibodies at room temperature for 2 h. Membranes were washed with TBST 3 times for 15 min each time. The membranes were subsequently incubated for 2--3 min by adding ECL chemical luminescent working solution, and exposed.

Oxidative stress response markers (MDA, SOD) evaluation
-------------------------------------------------------

The primary fetal rat hippocampal neurons cells were placed 6-well plates. After the treatment of drugs and oxygen-glucose deprivation, the cells were digested by trypsin. The cells were broken by ultrasound (300W, broken 25 s, and intermittent 25 s). After centrifugation and collection of supernatants, the MDA and SOD were detected by the kit provided by Nanjing Institute of Bioengineering using a blood gas analyzer (Analog Devices, Inc., USA), and the protein content was determined by Bradford method.

Statistical analysis
--------------------

Data processing was performed using SPSS 18.0 statistical software. The statistical data with normal distribution are expressed as mean ±SD. Comparison before and after treatment and the comparison between the 2 groups were performed by *t* test. The normally distributed data were subjected to multiple comparisons by Tukey's method in one-way ANOVA. P\<0.05 was considered statistically significant (the confidence level was set up at 95%), and P\<0.01 was statistically significant (the confidence level was set up at 99%).

Results
=======

Neurological assessment of patients
-----------------------------------

We estimated the effect of metformin on neurological function in patients with acute stroke complicated with type 2 diabetes. As shown in [Table 1](#t1-medscimonit-25-2186){ref-type="table"}, there was no significant difference between the 2 groups before treatment in MMSE, NIHSS, and ADL scores (P\>0.05). After 2 weeks of treatment, the MMSE and ADL scores of the patients in the 2 groups increased significantly, while the NIHSS scores decreased significantly. Compared with those before treatment, the difference between the 2 groups was statistically significant (P\<0.05). Moreover, when comparing the metformin combined treatment group with the insulin group, MMSE and ADL were increased and NIHSS was decreased significantly (P\<0.05).

Oxidative stress index in patients
----------------------------------

We estimated the effect of metformin on oxidative stress in patients with acute stroke complicated with type 2 diabetes. According to [Table 2](#t2-medscimonit-25-2186){ref-type="table"}, there was no significant difference in malondialdehyde (MDA), glutathione peroxidase (GSH-PX) and superoxide dismutase (SOD) between the 2 groups before treatment (P\>0.05). After 2 weeks of treatment in patients of the 2 groups, malondialdehyde (MDA) decreased significantly, glutathione peroxidase (GSH-PX) and superoxide dismutase (SOD) increased significantly, compared with before treatment (P\<0.05). Compared to the insulin group, the levels of MDA, SOD, and GSH-PX significantly decreased in the metformin group.

The effect of metformin on hippocampal neurons morphology
---------------------------------------------------------

The effect of metformin on the morphology of the primary fetal rat hippocampal neurons in oxygen deprivation was observed. In the oxygen-glucose deprivation model group, many of the primary fetal rat hippocampal neurons showed apoptosis, necrosis, cell contraction, and limited growth. The metformin group had partial necrosis and apoptosis of the primary fetal rat hippocampal neuron cells, which was lower than in the oxygen-glucose deprivation model group ([Figure 1](#f1-medscimonit-25-2186){ref-type="fig"}).

The effect of metformin on survival rate in the hippocampal cell culture
------------------------------------------------------------------------

MTT assay was used to observe the effect of metformin on the survival rate of the primary fetal rat hippocampal neurons induced by oxygen-glucose deprivation. The survival rate of the primary fetal rat hippocampal neurons in the control group was 100%, while the survival rate of the primary fetal rat hippocampal neurons in the oxygen-glucose deprivation group was 38.7±5.24%, and the survival rate in the metformin group was 72.3±7.26%. The survival rate of the oxygen-glucose deprivation group was significantly lower than that of the control group (P\<0.01). The survival rate of the metformin group was significantly higher than that of the oxygen-glucose deprivation group (P\<0.01) ([Figure 2](#f2-medscimonit-25-2186){ref-type="fig"}).

The effect of metformin on the apoptosis rate in the hippocampal cell culture
-----------------------------------------------------------------------------

The effect of metformin on the apoptosis rate of the primary fetal rat hippocampal neurons in oxygen-glucose deprivation was observed by TUNEL staining. The TUNEL-positive cells were stained green, DAPI staining was blue, and the number of TUNEL-positive cells divided by the number of DAPI staining was the rate of apoptosis. The apoptosis rate of the control group was 1.1±0.3%, the rate of apoptosis in the model group was 72±4.8%, and the rate of apoptosis in the metformin group was 33±5.9%. The apoptotic rate in the model group was significantly higher than that in the control group (P\<0.01), and the apoptosis rate in metformin group was significantly lower than that in the model group (P\<0.01) ([Figure 3](#f3-medscimonit-25-2186){ref-type="fig"}).

The effect of metformin on apoptotic pathway in the hippocampal cell culture
----------------------------------------------------------------------------

The effect of metformin on the AMPK/mTOR signaling pathway and apoptotic protein in the primary fetal rat hippocampal neurons induced by oxygen-glucose deprivation was observed. The expression of AMPK, pAMPK, and Bax in the model group increased significantly compared with the control group, and the expression of mTOR and Bcl-2 in the model group was significantly lower than that in the control group (P\<0.05). The expression of AMPK, pAMPK, and Bax in metformin group was significantly lower than that in the model group, and the expression of mTOR and Bcl-2 in the metformin group was significantly higher than that in the model group (P\<0.05) ([Figure 4](#f4-medscimonit-25-2186){ref-type="fig"}).

The effect of metformin on oxidative stress response in the hippocampal cell culture
------------------------------------------------------------------------------------

The MDA content in the model group was significantly higher than that in the control group (P\<0.05). The MDA content in metformin group was significantly lower than that in the model group (P\<0.05). SOD activity in the model group was significantly lower than that in the control group (P\<0.05). The SOD activity in metformin group was significantly higher than that in the model group (P\<0.05) ([Figure 5](#f5-medscimonit-25-2186){ref-type="fig"}).

Discussion
==========

Metformin is a clinically common first-line agent for the treatment of type 2 diabetes, which can reduce insulin resistance, reduce liver glycogen formation, promote the use of peripheral glucose, and then effectively control blood glucose levels. A number of epidemiological studies have shown that long-term metformin treatment in type 2 diabetes can reduce the risk and the severity of cerebrovascular disease \[[@b5-medscimonit-25-2186],[@b6-medscimonit-25-2186],[@b14-medscimonit-25-2186]--[@b16-medscimonit-25-2186]\]. A number of basic studies have shown that the use of metformin to pre-treat cerebral ischemia in rats can reduce the area of cerebral infarction, reduce neuronal apoptosis, and improve neurological deficits \[[@b14-medscimonit-25-2186],[@b17-medscimonit-25-2186]\]. The use of metformin after cerebral ischemia in rats can reduce blood-brain barrier damage and improve cognitive function \[[@b12-medscimonit-25-2186],[@b13-medscimonit-25-2186]\]. The present study shows that, compared with insulin alone, patients with type 2 diabetes treatment with metformin combined with insulin treatment had significantly higher MMSE and ADL scores, but NIHSS scores decreased significantly, which shows that metformin can improve the neurological deficit and improve cognitive function in patients with acute stroke with type 2 diabetes.

To demonstrate the mechanism underlying the neuroprotective effects of metformin, fetal rat hippocampal neuronal cell culture was used to study the molecular mechanism. Oxygen-glucose deprivation of the primary fetal rat hippocampal neurons can mimic the process of ischemic stroke at the cellular level \[[@b18-medscimonit-25-2186]\], and our study showed that the apoptotic rate of the primary fetal rat hippocampal neurons in the metformin group was significantly lower than that in the oxygen-glucose deprivation model group, and the survival rate was significantly increased (P\<0.01), indicating that metformin has neuroprotective effects on oxygen deprived primary fetal rat hippocampal neurons.

In patients with acute brain injury due to cerebral ischemia and hypoxia, the brain tissue exhibits a high level of oxidative stress, which induces the production of free radicals and inflammatory factors, further aggravating the damage of brain tissue and nerve cells \[[@b19-medscimonit-25-2186],[@b20-medscimonit-25-2186]\]. MDA, SOD, and GSH-PX are all markers of oxidative stress, and MDA is the end-product of lipid peroxidation. SOD is a metalloenzyme that scavenges oxygen free radicals, GSH-PX is an antioxidant that blocks the cascade of oxidative stress systems and scavenges oxygen free radicals, MDA, and SOD, and GSH-PX reflects the level of oxidative stress in the body \[[@b2-medscimonit-25-2186],[@b21-medscimonit-25-2186],[@b22-medscimonit-25-2186]\]. The clinical trials in this study showed that serum MDA levels were significantly decreased in patients with acute stroke treated with metformin combined with insulin, and SOD activity and GSH-PX levels were significantly increased; the basic experiment also reached the same conclusion. This indicates that metformin can improve neurological function by reducing the level of oxidative stress.

AMPK is a serine/threonine protein kinase that acts as an energy receptor and is involved in many physiological processes such as cell growth, metabolism, and apoptosis. Research shows that metformin can reduce brain tissue inflammation through the AMPK pathway, and reduce the production of inflammatory cytokines, thereby reducing damage to the blood-brain barrier and promoting nerve repair \[[@b14-medscimonit-25-2186],[@b23-medscimonit-25-2186]--[@b25-medscimonit-25-2186]\]. The present study shows that metformin can improve apoptosis of the primary fetal rat hippocampal neurons induced by oxygen-glucose deprivation. After metformin treatment, the expression of AMPK, pAMPK, and Bax was significantly decreased, and the expression of mTOR and Bcl-2 was significantly increased. This suggests that metformin inhibits apoptosis of the primary fetal rat hippocampal neurons through the AMPK/mTOR signaling pathway, and then plays a neuroprotective role. This study agrees with other studies \[[@b5-medscimonit-25-2186]\] showing that metformin has neuroprotective effects on stroke in rats, and may be related to oxidative stress, endothelial nitric oxide synthase activation, angiogenesis, and autophagy \[[@b26-medscimonit-25-2186]--[@b29-medscimonit-25-2186]\].

Metformin may be able to promote angiogenesis and neuronal regeneration in the brain. Metformin was used to intervene in the model of cerebral ischemia in mice, and the density of neovascularization in the cerebral ischemic area was significantly increased, and the neuronal cells showed obvious regeneration, which actively promoted nerve repair \[[@b26-medscimonit-25-2186]--[@b32-medscimonit-25-2186]\]. The present study demonstrates that metformin may play a neuroprotective role through the AMPK/mTOR signaling pathway and oxidative stress. However, further studies on animal vascular regeneration, nerve cell regeneration, and other possible mechanisms are needed.

Conclusions
===========

In summary, metformin can improve neurological function and oxidative stress in patients with acute stroke and type 2 diabetes, and its mechanism may be related to the AMPK/mTOR signaling pathway and oxidative stress.

**Source of support:** Departmental sources

**Conflict of interest**

None.

![The morphological observation of the primary fetal rat hippocampal neurons in each group (×200). (**A**: Control group; **B**: Model group; **C**: Metformin group).](medscimonit-25-2186-g001){#f1-medscimonit-25-2186}

![The effect of metformin on the survival rate of the primary fetal rat hippocampal neurons under oxygen-glucose deprivation. (\*\* P\<0.01 compared with the control group, there was a statistically significant difference; ^\#\#^ P\<0.01 compared with the model group, the difference was statistically significant).](medscimonit-25-2186-g002){#f2-medscimonit-25-2186}

![Effect of metformin on the apoptotic rate of the primary fetal rat hippocampal neurons under oxygen-glucose deprivation. (TUNEL-stained green cells showed apoptosis-positive cells, DAPI-stained blue as nucleated cells, Merge stained with TUNEL and DAPI. Apoptosis rate comparison: \*\* P\<0.01 compared with control group, the difference was statistically significant; ^\#\#^ compared with the model group P\<0.01, the difference was statistically significant).](medscimonit-25-2186-g003){#f3-medscimonit-25-2186}

![Effect of metformin on the expression of protein in the primary fetal rat hippocampal neurons under oxygen-glucose deprivation. (\*\* P\<0.01 compared with the control group, the difference was statistically significant; ^\#\#^ compared with the model group P\<0.01, the difference was statistically significant).](medscimonit-25-2186-g004){#f4-medscimonit-25-2186}

![Effect of metformin on MDA and SOD in the primary fetal rat hippocampal neurons under oxygen-glucose deprivation. (\*\* P\<0.01 compared with the control group, the difference was statistically significant; ^\#\#^ compared with the model group P\<0.01, the difference was statistically significant).](medscimonit-25-2186-g005){#f5-medscimonit-25-2186}

###### 

Effect of metformin on oxidative stress in patients with acute stroke complicated with type 2 diabetes (n=40).

  Group                                   MMSE score   NIHSS score                                                                                                        ADL score                                                                                                                                   
  --------------------------------------- ------------ ------------------------------------------------------------------------------------------------------------------ ------------ ---------------------------------------------------------------------------------------------------------------- ------------- -------------------------------------------------------------------------------------------------------------------
  Metformin combination treatment group   22.18±1.93   25.16±2.16[a](#tfn1-medscimonit-25-2186){ref-type="table-fn"}[b](#tfn2-medscimonit-25-2186){ref-type="table-fn"}   19.66±8.48   7.4±4.72[a](#tfn1-medscimonit-25-2186){ref-type="table-fn"}[b](#tfn2-medscimonit-25-2186){ref-type="table-fn"}   26.45±9.19    63.86±12.20[a](#tfn1-medscimonit-25-2186){ref-type="table-fn"}[b](#tfn2-medscimonit-25-2186){ref-type="table-fn"}
  Insulin group                           22.21±1.96   23.15±1.95[a](#tfn1-medscimonit-25-2186){ref-type="table-fn"}                                                      19.72±7.92   10.6±5.62[a](#tfn1-medscimonit-25-2186){ref-type="table-fn"}                                                     26.82±10.28   44.15±13.27[a](#tfn1-medscimonit-25-2186){ref-type="table-fn"}
  t value                                 0.687        8.116                                                                                                              0.839        6.525                                                                                                            0.718         8.382
  P value                                 0.465        \<0.001                                                                                                            0.341        \<0.001                                                                                                          0.432         \<0.001

Compared with before treatment, P\<0.05, the difference was statistically significant;

compared with the control group, P\<0.05, the difference was statistically significant.

###### 

Effect of metformin on oxidative stress in patients with acute cerebral stroke and type 2 diabetes (n=40).

  Group                                   MDA (μmol/L)   SOD (U/L)                                                                                                         GSH-PX (U/L)                                                                                                                                   
  --------------------------------------- -------------- ----------------------------------------------------------------------------------------------------------------- -------------- ------------------------------------------------------------------------------------------------------------------ ------------ ------------------------------------------------------------------------------------------------------------------
  Metformin combination treatment group   4.95±0.96      2.23±0.74[a](#tfn3-medscimonit-25-2186){ref-type="table-fn"}[b](#tfn4-medscimonit-25-2186){ref-type="table-fn"}   27.46±9.18     36.72±9.92[a](#tfn3-medscimonit-25-2186){ref-type="table-fn"}[b](#tfn4-medscimonit-25-2186){ref-type="table-fn"}   155.4±24.7   188.2±20.1[a](#tfn3-medscimonit-25-2186){ref-type="table-fn"}[b](#tfn4-medscimonit-25-2186){ref-type="table-fn"}
  Insulin group                           4.97±0.87      3.29±0.83[a](#tfn3-medscimonit-25-2186){ref-type="table-fn"}                                                      27.32±8.92     31.81±8.97[a](#tfn3-medscimonit-25-2186){ref-type="table-fn"}                                                      153.6±26.8   164.3±27.8[a](#tfn3-medscimonit-25-2186){ref-type="table-fn"}
  t value                                 1.122          5.721                                                                                                             0.542          7.246                                                                                                              0.361        7.324
  P value                                 0.286          \<0.001                                                                                                           0.637          \<0.001                                                                                                            0\. 794      \<0.001

Compared with before treatment, P\<0.05, the difference was statistically significant;

compared with the control group, P\<0.05, the difference was statistically significant.
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